Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program
Last Updated: Tuesday, May 11, 2021
Among patients with JAK2V617F mutation–positive polycythemia vera, long-term treatment with HDAC inhibitor givinostat was well tolerated and efficacious, with only 10% of patients reporting grade 3 treatment-related adverse events, but no grade 4 or 5, and a > 80% overall response rate at 4-year follow-up.
Advertisement
News & Literature Highlights
